AstraZeneca
AZN
1,516 hedge funds and large institutions have $198B invested in AstraZeneca in 2026 Q2 according to their latest regulatory filings, with 265 funds opening new positions, 528 increasing their positions, 499 reducing their positions, and 123 closing their positions.
250% more capital inflows, than outflows
Capital inflows: $19.7B | Capital outflows: $5.62B
115% more first-time investments, than exits
New positions opened: 265 | Existing positions closed: 123
9% more funds holding
Funds holding: 1,392 → 1,516 (+124)
3.9% more ownership
Funds ownership: 48.84% → 52.74% (+3.9%)
6% more repeat investments, than reductions
Existing positions increased: 528 | Existing positions reduced: 499
17% less funds holding in top 10
Funds holding in top 10: 72 → 60 (-12)
42% less call options, than puts
Call options by funds: $704M | Put options by funds: $1.21B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.97B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$900M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$546M |
| 4 |
Causeway Capital Management
Los Angeles,
California
|
+$364M |
| 5 |
AEGON Asset Management (UK)
Edinburgh,
United Kingdom
|
+$358M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$540M |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$318M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$257M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$241M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$229M |
AZN Hedge Fund Activity: Q2 2026 in Review
1,516 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2026, worth a combined $198B — up 31% from $152B a quarter earlier.
Buyers outnumbered sellers: 265 funds opened new AZN positions and 123 closed out — a net gain of 142 holders — while 528 added to existing stakes and 499 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $1.97B. The largest seller was T. Rowe Price Associates, cutting an estimated $540M.
- 1,516 institutional investors held AstraZeneca (AZN) as of Q2 2026, up from 1,392 in Q1 2026.
- Funds reported $198B of AstraZeneca stock for Q2 2026, up 31% quarter-over-quarter.
- 265 funds opened new AstraZeneca positions in Q2 2026 and 123 closed out, a net change of +142 holders.
- The largest AstraZeneca buyer in Q2 2026 was Royal Bank of Canada, an estimated $1.97B added.
- The largest AstraZeneca seller in Q2 2026 was T. Rowe Price Associates, an estimated $540M sold.
Based on aggregated 13F filings for Q2 2026.